Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry

Abstract

Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation.